Items where Author is "Zippelius, A."

2016

Thommen, D. and Uhlenbrock, F. and Herzig, P. and Savic Prince, S. and Moersig, W. and Lardinois, D. and Zippelius, A.. (2016) 66P Highly exhausted PD-1hi T cell subsets in human NSCLC are co-defined by the predominant expression of distinct inhibitory receptors and correlate with clinical outcome. Journal of Thoracic Oncology, 11 (4 Suppl). S83.

Rothschild, S. I. and Hagmann, R. and Zippelius, A.. (2016) 92P: Validation of prognostic scores in small cell lung cancer. J Thorac Oncol, 11 (4 Suppl). pp. 96-97.

Muller, P. and Thommen, D. S. and Zippelius, A.. (2016) Agonistic anti-CD40 therapy synergizes with LAG-3-blocking antibodies. Int J Clin Pharmacol Ther, 55 (8). pp. 692-694.

Ruiz, C. and Kustermann, S. and Pietilae, E. and Vlajnic, T. and Baschiera, B. and Arabi, L. and Lorber, T. and Oeggerli, M. and Savic, S. and Obermann, E. and Singer, T. and Rothschild, S. I. and Zippelius, A. and Roth, A. B. and Bubendorf, L.. (2016) Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine. PLoS One, 11 (8). e0160807.

Schlosser, H. A. and Drebber, U. and Kloth, M. and Thelen, M. and Rothschild, S. I. and Haase, S. and Garcia-Marquez, M. and Wennhold, K. and Berlth, F. and Urbanski, A. and Alakus, H. and Schauss, A. and Shimabukuro-Vornhagen, A. and Theurich, S. and Warnecke-Ebertz, U. and Stippel, D. L. and Zippelius, A. and Buttner, R. and Hallek, M. and Holscher, A. H. and Zander, T. and Monig, S. P. and von Bergwelt-Baildon, M.. (2016) Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. Oncoimmunology, 5 (5). e1100789.

Theurich, S. and Rothschild, S. I. and Hoffmann, M. and Fabri, M. and Sommer, A. and Garcia-Marquez, M. and Thelen, M. and Schill, C. and Merki, R. and Schmid, T. and Koeberle, D. and Zippelius, A. and Baues, C. and Mauch, C. and Tigges, C. and Kreuter, A. and Borggrefe, J. and von Bergwelt-Baildon, M. and Schlaak, M.. (2016) Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. Cancer Immunol Res, 4 (9). pp. 744-754.

2015

Conen, K. and Mosna-Firlejczyk, K. and Rochlitz, C. and Wicki, A. and Itin, P. and Arnold, A. W. and Gross, M. and Zimmermann, F. and Zippelius, A.. (2015) Vemurafenib-induced radiation recall dermatitis: case report and review of the literature. Dermatology, 230 (1). pp. 1-4.

2014

Tse, B. W. and Collins, A. and Oehler, M. K. and Zippelius, A. and Heinzelmann-Schwarz, V. A.. (2014) Antibody-based immunotherapy for ovarian cancer: where are we at? Annals of oncology, Vol. 25, H. 2. pp. 322-331.

Müller, P. and Martin, K. and Theurich, S. and Schreiner, J. and Savic, S. and Terszowski, G. and Lardinois, D. and Heinzelmann-Schwarz, V. A. and Schlaak, M. and Kvasnicka, H. M. and Spagnoli, G. and Dirnhofer, S. and Speiser, D. E. and von Bergwelt-Baildon, M. and Zippelius, A.. (2014) Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunology Research, 2 (8). pp. 741-755.

2008

Tinguely, M. and Jenni, B. and Knights, A. and Lopes, B. and Korol, D. and Rousson, V. and Curioni Fontecedro, A. and Cogliatti, S. B. and Bittermann, A. G. and Schmid, U. and Dommann-Scherrer, C. and Maurer, R. and Renner, C. and Probst-Hensch, N. M. and Moch, H. and Knuth, A. and Zippelius, A.. (2008) MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer science, Vol. 99, H. 4. pp. 720-725.

Curioni-Fontecedro, A. and Knights, A. J. and Tinguely, M. and Nuber, N. and Schneider, C. and Thomson, C. W. and von Boehmer, L. and Bossart, W. and Pahlich, S. and Gehring, H. and Moch, H. and Renner, C. and Knuth, A. and Zippelius, A.. (2008) MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia, Vol. 22, no. 8. pp. 1646-1648.